Evidence map›Paper›PMID 29509566›Full record

ArticleSexually transmitted diseases2018

Prevalence of Mycoplasma genitalium and Azithromycin-resistant Infections Among Remnant Clinical Specimens, Los Angeles.

Lao-Tzu Allan-Blitz, Elisa Mokany, Shelley Campeau, Rachel Wee, Chelsea Shannon, Jeffrey D Klausner

Abstract read
In one paragraph

Article in Sexually transmitted diseases, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
1.1field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.

  1. Pooled it
  2. Drug resistance ofFrontiers in cellular and infection microbiology · 2026
    Review
  3. Review
  4. Mycoplasma genitalium in the US (MyGeniUS): Surveillance Data From Sexual Health Clinics in 4 US Regions.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023
    Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Lao-Tzu Allan-Blitz
Elisa MokanySpeeDx Pty Ltd., Sydney, Australia.
Shelley CampeauDepartment of Pathology and Laboratory Medicine, David Geffen School of Medicine, and.
Rachel WeeSpeeDx Pty Ltd., Sydney, Australia.
Chelsea Shannon
Jeffrey D Klausner
University of California, Los Angeles · US

Funding

South American Program in HIV Prevention Research (SAPHIR)R25MH087222 · NIMH · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI JESSE LAWTON CLARK, Karin Nielsen · 2011 to 2026
$3.9M
Reducing excess broad-spectrum antibiotic use in gonorrheaR21AI117256 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI KLAUSNER, JEFFREY DAVID · 2016 to 2017
$424k
Controlling Drug Resistant Gonorrhea with Real-Time PCR Susceptibility TestingR21AI109005 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI KLAUSNER, JEFFREY DAVID · 2014 to 2015
$362k
NIAID NIH HHS R21 AI109005NIAID NIH HHS R21 AI117256NIMH NIH HHS R25 MH087222
6 · The paper itself

Abstract

backgroundMycoplasma genitalium is an important cause of bacterial sexually transmitted diseases. Diagnosis and susceptibility testing of M. genitalium are limited by the fastidious nature of the organism. Therefore, the prevalence of infection and azithromycin resistance are poorly studied.

methodsWe conducted an exploratory study on remnant clinical specimens. We collected remnant DNA from consecutive urine samples and clinical swabs (cervical/vaginal, rectal, and pharyngeal) previously tested for Neisseria gonorrhoeae and Chlamydia trachomatis using the Cobas 4800 CT/NG assay (Roche Molecular Systems, Pleasanton, CA) between March-April 2017 from across the University of California, Los Angeles Health System. We then retrospectively tested all specimens with the ResistancePlus MG (550) kit, a molecular assay for the detection of M. genitalium and genetic mutations associated with azithromycin resistance.

resultsAmong 500 specimens, the prevalence of M. genitalium was 1.1% (95% confidence interval [CI], 0.04%-3.0%) in urine samples (n = 362), 17.4% (95% CI, 5.7%-39.6%) in rectal swabs (n = 23), and 1.9% (95% CI, 0.3%-7.3%) in cervical/vaginal swabs (n = 106). The prevalence of N. gonorrhoeae was 0.6% in urine samples and 4.3% in rectal swabs, whereas the prevalence of C. trachomatis was 2.2% in urine samples, 4.3% in rectal swabs and 3.8% in cervical/vaginal swabs. Of the 10 M. genitalium positive specimens, 8 (80.0%) had a mutation associated with azithromycin resistance.

conclusionsThe prevalence of M. genitalium infection in our population varied by anatomic site of infection. Most M. genitalium infections had at least 1 mutation associated with azithromycin resistance.

Indexed as

Anti-Bacterial AgentsAzithromycinCervix UteriDNA, BacterialDrug Resistance, BacterialFemaleHumansLos AngelesMutationMycoplasma genitaliumMycoplasma InfectionsPharynxPrevalenceRectumRetrospective StudiesSexually Transmitted Diseases, BacterialAnti-Bacterial AgentsAzithromycinDNA, Bacterial

Identifiers

PMID29509566
PMCPMC6086743
OpenAlexW2790924619

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.